Dabigatran

Composition

The formulation Contains dabigatran etexilate mesilate as the active ingredient.

Indications

Prevention of stroke and systemic embolism in non-valvular atrial fibrillation, treatment and prevention of deep vein

Side effects

gastrointestinal upset, bleeding, and hematoma formation

Precautions

Use with caution in patients with renal impairment or a history of bleeding disorders. Monitor renal function and signs of bleeding regularly.

Contraindications

Severe hepatic dysfunction, bone marrow suppression

Dosage and administration

typically taken twice daily with or without food

Countries

USA, Canada, EU

Available Forms

Capsules

Manufacturing Services

Third Party Manufacturing Company WHO, GMP, EUGMP, USFDA, In India | Contract Manufacturing Organization (CMO) WHO, GMP, EUGMP, USFDA Services in India, Mumbai, Navi Mumbai| Contract Development and Manufacturing Organization (CDMO) WHO, GMP, EUGMP, USFDA - Services in India | Pharmaceutical Contract Manufacturing Company WHO, GMP, EUGMP, USFDA in Navi Mumbai, India | Top Pharmaceutical Product Exporters, Suppliers, Distributer WHO, GMP, EUGMP, USFDA in Mumbai